SGS opening new biopharma testing lab in Geneva

By Melissa Fassbender

- Last updated on GMT

(Image: Getty/Zmaj88)
(Image: Getty/Zmaj88)

Related tags SGS Biopharmaceutical Analytical chemistry Bioanalytical Laboratory

The analytical and bioanalytical contract solutions provider SGS is expanding its biopharmaceutical testing capabilities in Geneva, Switzerland.

SGS​ also provides Phase I-IV clinical trial management, with services including data management and statistics, PK/PD (pharmacokinetic/pharmacodynamic) modeling and simulation, pharmacovigilance, and regulatory consultancy.

The new 200 square meter laboratory, slated to open by the end of Q3 2018, will be equipped with several instruments and complements the company’s existing 800 square meter facility.

Upon completion, the laboratory will offer full ICH Q6B​ physico-chemical characterization of biological products.

According to SGS, the expansion responds to the “growing need for biopharmaceutical studies during the early and late phase of characterization, as required by the ICH guidelines.”

Services to be offered include circular dichroism (CD), Fourier-transform infrared spectroscopy (FTIR), extrinsic and intrinsic fluorescence, analytical ultracentrifugation (SV-AUC), size exclusion chromatography with multi-angle light scattering (SEC-MALS), dynamic light scattering (DLS), and differential scanning calorimetry (DSC).

“To fulfil regulatory requirements, the biopharmaceutical industry increasingly expects its contract service providers to offer comprehensive characterization capabilities from a single location,”​ said Luc-Alain Savoy, managing director of SGS Life Sciences Geneva in a press release.

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Related suppliers

Follow us


View more